BRIEF published on 08/08/2025 at 02:20, 1 year 1 month ago CureVac Settles Patent Dispute with Pfizer/BioNTech MRNA Technology CureVac Pfizer/BioNTech Patent Resolution Vaccine Royalties
PRESS RELEASE published on 08/08/2025 at 02:15, 1 year 1 month ago CureVac Announces Resolution of Patent Litigation with Pfizer/BioNTech CureVac resolves patent litigation with Pfizer/BioNTech related to mRNA-based COVID-19 vaccines, receiving $790 million and non-exclusive license agreements BioNTech MRNA Technology CureVac Patent Litigation Pfizer
BRIEF published on 06/24/2025 at 22:14, 1 year 2 months ago CureVac publie les résultats de son assemblée générale annuelle CureVac Nominations Au Conseil D'administration Commissaires Aux Comptes Technologie De L'ARNm Assemblée Annuelle
BRIEF published on 06/24/2025 at 22:14, 1 year 2 months ago CureVac Reports Outcomes of Annual General Meeting MRNA Technology Annual Meeting Board Appointments Auditors CureVac
PRESS RELEASE published on 06/24/2025 at 22:09, 1 year 2 months ago CureVac Announces Voting Results of General Meeting CureVac announces voting results of Annual General Meeting, including new Management Board and Supervisory Board appointments. KPMG reappointed as external auditors Annual General Meeting Appointments Voting Results KPMG CureVac
BRIEF published on 05/20/2025 at 13:05, 1 year 4 months ago CureVac Reports Q1 2025 Financials and Business Developments Financial Results Revenue Patents Oncology Pipeline R&D Developments
BRIEF published on 05/20/2025 at 13:05, 1 year 4 months ago CureVac publie ses résultats financiers et ses développements commerciaux pour le premier trimestre 2025 Résultats Financiers Brevets Revenu Pipeline En Oncologie Développements En R&D
PRESS RELEASE published on 05/20/2025 at 13:00, 1 year 4 months ago CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates CureVac announces financial results for Q1 2025 and updates on lung cancer and glioblastoma trials, urinary tract infection vaccine, and mRNA patents. Cash position strong at €438.3 million Financial Results Oncology Pipeline CureVac Q1 2025 MRNA Patents
BRIEF published on 05/15/2025 at 22:15, 1 year 4 months ago CureVac Gains Favorable Patent Decision Against BioNTech BioNTech MRNA Technology CureVac Patent Litigation European Patent Office
BRIEF published on 05/15/2025 at 22:15, 1 year 4 months ago CureVac obtient une décision favorable en matière de brevets contre BioNTech BioNTech CureVac Technologie De L'ARNm Office Européen Des Brevets Litiges En Matière De Brevets
Published on 09/19/2026 at 00:55, 2 days 7 hours ago Gossan Resources Announces Changes to Board and Management
Published on 09/18/2026 at 22:00, 2 days 10 hours ago Silver Tiger Announces Results of Annual and Special Meeting
Published on 09/18/2026 at 20:35, 2 days 12 hours ago Only 11% of Marketers Expect Google Search to Be Their Customers' Main Starting Point in Two Years
Published on 09/18/2026 at 14:30, 2 days 18 hours ago AIAI Holdings to Obtain a Controlling Position in Messier 42 Marketing Agreement
Published on 09/21/2026 at 08:30, 22 minutes ago ASMAX at CIMAMotor 2026: Rethinking What a Motorcycle Intercom Should Be
Published on 09/21/2026 at 08:05, 47 minutes ago Demand for services rising faster than charities can respond, CAF research finds
Published on 09/21/2026 at 07:42, 1 hour 10 minutes ago Berentzen Group and Sazerac to create a leading spirits platform in Europe: Takeover offer for Berentzen-Gruppe Aktiengesellschaft announced
Published on 09/21/2026 at 07:00, 1 hour 53 minutes ago Peugeot Invest takes a stake in Mérieux NutriSciences
Published on 09/21/2026 at 07:00, 1 hour 53 minutes ago Peugeot Invest entre au capital de Mérieux NutriSciences
Published on 09/18/2026 at 18:34, 2 days 14 hours ago Disclosure of transactions in own shares from September 14 to September 18, 2026
Published on 09/18/2026 at 18:34, 2 days 14 hours ago Déclaration hebdomadaire d'opérations effectuées du 14 au 18 septembre 2026
